Sunesis reported results from an Phase Ib/II study sponsored by MD Anderson during the European Hematology Association meeting in June 2016, detailing the effect of a combination of Qinprezo and Dacogen for the frontline treatment of patients with acute myeloid leukemia (AML) and those with myelodysplastic syndrome (MDS) unfit for intensive therapy. The 63-person open-label trial demonstrated a median overall survival of 16.1 months at the 70mg/m2 Qinprezo dose, over twice that of either of the drugs alone.
